BioAge Labs, Inc (BIOA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $255.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
BioAge Labs, Inc (BIOA) Stock Forecast
Analysts expect BioAge Labs (BIOA) to earn -$2.57 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.92M. Of 10 analysts, 7 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.10, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 70% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 20.0% |
| Buy | 5 | 50.0% |
| Hold | 3 | 30.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 110.1%.
- Fiscal year ending Dec 31, 2026
- -$2.57
- EPS consensus, revenue $6.92M
- Fiscal year ending Dec 31, 2027
- -$2.62
- EPS consensus, revenue $14.54M
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.57 | -$2.65 to -$2.50 | 7 | $6.92M | $5.52M to $8.63M | 11 |
| Dec 31, 2027 | -$2.62 | -$3.12 to -$1.93 | 8 | $14.54M | N/A | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.70 for the quarter ending Dec 31, 2026 to -$0.69 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.70 | -$0.81 to -$0.63 | 13 | $1.60M | N/A | 12 |
| Mar 31, 2027 | -$0.69 | -$0.78 to -$0.58 | 4 | $383330 | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.37.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.57 | -$2.43 | -$2.37 | -$2.37 | -$2.37 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.62 | -$2.50 | -$2.41 | -$2.41 | -$2.36 | N/A |
| Quarter ending Mar 31, 2027 | -$0.69 | -$0.63 | -$0.56 | -$0.56 | -$0.56 | N/A |
Frequently Asked Questions About BIOA
What is the BIOA stock forecast?
Consensus analyst estimates put BioAge Labs's EPS at -$2.57 for the fiscal year ending Dec 31, 2026, on revenue of $6.92M. The consensus rating from 10 analysts is Buy.
How do analysts rate BIOA stock?
Of 10 analysts covering BioAge Labs, 2 rate it Strong Buy, 5 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BIOA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.57, with estimates from -$2.65 to -$2.50 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.62, with estimates from -$3.12 to -$1.93 from 8 analysts.
What revenue do analysts expect from BioAge Labs next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.92M, with estimates from $5.52M to $8.63M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $14.54M.
How many analysts cover BIOA?
10 analysts rate BioAge Labs stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BIOA pages: Overview, Earnings, Forecast, Financials, Competitors